Skip to main content
Top

11-06-2015 | Gastric cancer | Book chapter | Article

8. Diagnosis, Staging, and Workup of Gastric Cancer

Authors: Arvind Sabesan, MD, Joseph J. Bennett, MD

Publisher: Springer International Publishing

Abstract

Gastric cancer remains a significant health issue and remains the 4th leading cause of cancer worldwide. Unfortunately, most disease is detected at a late stage, where symptoms and physical exam findings usually indicate advanced or metastatic disease. Although symptoms may help identify the presence and location of malignancy, diagnosis is largely based on early endoscopy. Endoscopy allows for characterization of the tumor as well as obtaining a tissue diagnosis. With the 7th edition of the American Joint Committee on Cancer (AJCC) staging manual, better understanding of disease has reorganized the staging groups as well as placed greater emphasis on lymph node involvement. The goals of staging are to predict long term survival as well as guide treatment options. Although the new AJCC staging system has improved compared to earlier versions, new nomograms may be a better predictor of survival and recurrence.
Workup of gastric cancer involves a select variety of diagnostic tests which include endoscopy, CT, endoscopic ultrasound (EUS), diagnostic laparoscopy, and positron emission tomography (PET) scan in order to stage patients. These tests can be used to stratify patients who are candidates for resection versus those who need palliative therapy. As technology, imaging, gene profiling, and tumor marker identification improve, disease may be detected at an earlier stage and improve overall survival for patients with gastric cancer.
Literature
1.
Kamangar F, Dores G, Anderson W. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.PubMedCrossRef
2.
Roder D. The epidemiology of gastric cancer. Gastric Cancer. 2002;5(1):5–11.PubMedCrossRef
3.
Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011;22(suppl 5):1–9.CrossRef
4.
Feig B, Ching C. The MD Anderson surgical oncology handbook. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2012.
5.
Chua Y, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol. 2007;14(10):2687–90.PubMedCrossRef
6.
Kelsen D. Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116. J Clin Oncol. 2000;18(suppl 1):32–4.
7.
Lee J, Kang W, Lim D, Park J, Park Y, Lim H, Sohn T, Noh J, Bae J, Kim S. Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): safety analysis. J Clin Oncol. 2009;27(15 S):4537.
8.
Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17(12):3077–79.PubMedCrossRef
9.
Kwee R, Kwee T. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25(15):2107–16.PubMedCrossRef
10.
Layke J, Lopez P. Gastric cancer: diagnosis and treatment options. Am Fam Physician. 2004;69(5): 1133–40.PubMed
11.
D’Angelica M, Gonen M, Brennan M, Turnbull A, Bains M, Karpeh M. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808.PubMedCentralPubMedCrossRef
12.
Longo W, Zucker K, Zdon M, Modlin I. Detection of early gastric cancer in an aggressive endoscopy unit. Am Surg. 1989;55(2):100–4.PubMed
13.
El Abiad R, Gerke H. Gastric cancer: endoscopic diagnosis and staging. Surg Oncol Clin N Am. 2012;21(1):1–19.PubMedCrossRef
14.
Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Lara-Santos L, Guilherme M, Moreira-Dias L et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc. 2003;57(4):498–504.PubMedCrossRef
15.
Mattar R, Andrade C, Difavero G, Gama-Rodrigues J, Laudanna A. Preoperative serum levels of CA 72—4, CEA, CA 19—9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Cl'in. 2002;57(3): 89–92.
16.
Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19—9, CA 72—4, and AFP levels in gastric cancer. Adv Ther. 2008;25(10):1075–84.PubMedCrossRef
17.
Graziosi L, Marino E, Cavazzoni E, Donini A. Prognostic value of the seventh AJCC/UICC TNM classification of non-cardia gastric cancer. World J Surg Oncol. 2013;11(1):103.PubMedCentralPubMedCrossRef
18.
Kattan M, Karpeh M, Mazumdar M, Brennan M. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21(19):3647–50.PubMedCrossRef
19.
Shah M, Khanin R, Tang L, Janjigian Y, Klimstra D, Gerdes H, Kelsen D. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17(9):2693–701.PubMedCentralPubMedCrossRef
20.
Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef
21.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Gastric cancer version 1. 2013.
22.
Bhari S, Sup Shim C, Hoon Kim J, Seop Jung I, Young Cho J, et al. Usefulness of three-dimensional, multidetector row CT (virtual gastroscopy and multiplanar reconstruction) in the evaluation of gastric cancer: a comparison with conventional endoscopy, EUS, and histopathology. Gastrointest Endosc. 2004;59(6):619–26.CrossRef
23.
Mocellin S, Marchet A, Nitti D. EUS for the staging of gastric cancer: a meta-analysis. Gastrointest Endosc. 2011;73(6):1122–34.PubMedCrossRef
24.
Karanicolas P, Elkin E, Jacks L, Atoria C, Strong V, Brennan M, Coit D. Staging laparoscopy in the management of gastric cancer: a population-based analysis. J Am Coll Surg. 2011;213(5):644–51.PubMedCrossRef
25.
Hopkins S, Yang G. FDG PET imaging in the staging and management of gastric cancer. J Gastrointest Oncol. 2011;2(1):39.PubMedCentralPubMed
26.
Brennan M, Karpeh Jr M. Surgery for gastric cancer: the American view. Semin Oncol. 1996;23(3):352–9.PubMed
27.
Caletti G, Fusaroli P. The rediscovery of endoscopic ultrasound (EUS) in gastric cancer staging. Endoscopy. 2012;44(06):553–5.PubMedCrossRef
28.
Cid’On E, Bustamante R. Gastric cancer: tumor markers as predictive factors for preoperative staging. J Gastrointest Cancer. 2011;42(3):127–30.CrossRef
29.
Crew K, Neugut A, Others. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354.PubMedCentralPubMed
30.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M. Cancer statistics, 2007. CA: Cancer J Clin. 2007;57(1):43–66.
31.
Wanebo H, Kennedy B, Chmiel J, Steele Jr G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American college of surgeons. Ann Surg. 1993;218(5):583.PubMedCentralPubMedCrossRef